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Accepted 21 February 2011AbstractObjective: This retrospective study aimed to investigate the use of an oxytocin antagonist in improving the pregnancy outcome of in vitro
fertilizationeembryo transfer (IVFeET) in patients with repeated implantation failure (RIF).
Materials and Methods: A total of 150 infertile couples with RIF undergoing IVFeETwere divided into three groups. Patients who did not receive
atosiban were used as controls (Group 1; n¼ 80). Forty patients received a single bolus dose (6.75 mg, 0.9 mL/vial) of atosiban before ET (Group
2), and 30 patients received a bolus dose of 6.75 mg atosiban followed by infusion at 18 mg/hr for 3 hours immediately after ET (Group 3).
Results: A significantly higher implantation rate (30.21%) was noted in Group 2 compared with Groups 1 and 3 (11.8% and 15.9%, respectively;
p¼ 0.0006). The clinical pregnancy rate of Group 2 (37.5%) was significantly higher than that of Groups 1 (12.5%) and 3 (20%) (p¼ 0.0057).
The live birth rate was significantly higher in Group 2 (35%) than in Groups 1 and 3 (10% and 16.67%, respectively; p¼ 0.0031).
Conclusion: These results suggest that IVFeET using lower dosage of atosiban may improve pregnancy outcomes of patients with RIF.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Embryo implantation is a complex process, and it is
believed that the success of embryo implantation depends on
embryo quality and endometrial receptivity. Repeated
implantation failure (RIF), despite the transfer of good-quality
embryos, is a distressing experience for patients who receive
in vitro fertilization (IVF) and increases the financial burden
on the couple or service provider [1]. RIF is generally defined
as failure to conceive after two or more unsuccessful embryo
transfer (ET) cycles or the transfer of a total of 10 or more
good-quality embryos [2,3]. The cause of RIF can be broadly
attributed to embryonic, uterine, genetic, hematological, or
immunological causes; however, RIF remains unexplained in* All authors declare no conflict of interest financially or commercially in
regard to this article.
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doi:10.1016/j.tjog.2011.04.003most cases [4]. As a result, there is considerable variation in
the approach to RIF treatment and management [2].
Arginine vasopressin V1 receptors are present on human
myometrial specimens obtained during cesarean section from
women at the end of pregnancy (from 32 weeks to term).
Oxytocin receptors increase in human parturition and are
significantly correlated with the frequency of uterine contrac-
tions [5]. Oxytocin and vasopressin receptors may play a role
in the regulation of labor, although increased oxytocin release
primarily initiates labor contractions. The mixed V1 arginine
vasopressin and oxytocin receptor antagonist atosiban is uterus
specific, decreases uterine contractions in pregnant women, and
is indicated for tocolysis in imminent premature birth [6].
Atosiban was developed specifically to treat preterm labor and
is widely used in many countries. A single bolus of atosiban
is indicated for acute tocolysis in term labor and arrest of
contractions before emergency caesarean section. Use of
a bolus dose of 6.75 mg atosiban followed by a maintained
dose is an effective management for the treatment of preterm
labor. Atosiban has little effect on maternal and fetal heartbeatscs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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have an immediate and profound effect comparable to that of
ritodrine on uterine contractions [7].
Good correlations between oxytocin receptor concentra-
tions and uterine contractility have been observed in both
pregnant and nonpregnant states [8]. Therefore, clinical eval-
uation of atosiban has been proposed for use in dysmenorrhea
and infertility cases [8,9]. As such, we have previously
reported on a couple experiencing RIF who conceived
successfully after an IVFeET, in which atosiban was admin-
istered intravenously during ET, and delivery of the second
and third triplets was delayed with the aid of an atosiban
infusion [10]. Recently, in a prospective, randomized, placebo-
controlled clinical study, treatment with atosiban before ET is
effective in priming of the uterus for implantation [11]. Ato-
siban increases the implantation and clinical pregnancy rates
and decreases the miscarriage rate, which may be the result of
increased endometrial perfusion and decreased uterine
contractility.
The objective of the present study was to determine if the
use of atosiban could improve the outcome (implantation rate,
clinical pregnancy rate, and live birth rate) of patients with
RIF undergoing IVFeET. In addition, the safety of atosiban
use was assessed.
Materials and methodsPatient selectionThis study was approved by the Institutional Review Board
of National Cheng Kung University Hospital. A total number
of 150 infertile couples, who attended the Assisted Repro-
ductive Technology Center at National Cheng Kung Univer-
sity Hospital, with a history of two or more previous IVF
failures after the transfer of good-quality embryos, were
collected retrospectively. The study was performed between
October 2006 and December 2009. After starting ovarian
stimulation and oocyte retrieval, patients received different
doses of atosiban (Tractocile; Ferring AB, Limhamn, Sweden)
infusion or no atosiban during the procedure of ET, in addition
to the medications that are used routinely in our IVF program.
The control group (Group 1; n¼ 80) included patients with
RIF who did not receive atosiban during ET. A placebo was
not administered because the variables that were chosen as
primary and secondary endpoints were objective and, thus, not
likely to be influenced by patients’ will. Forty patients
received a single bolus dose (6.75 mg, 0.9 mL/vial) of atosiban
intravenously before ET (Group 2), with an infusion time of
more than 1 minute. Thirty patients received a bolus dose of
6.75 mg atosiban intravenously followed by continuous infu-
sion at 18 mg/hr for 3 hours (Group 3).Ovarian stimulationAll of the women in this study underwent a controlled
ovulation hyperstimulation protocol as determined by their
primary physician depending on patient age, antral folliclecount, and serum follicle-stimulating hormone levels. Proto-
cols included a long luteal-phase gonadotropin-releasing
hormone (GnRH) agonist protocol, a short GnRH agonist
protocol, or the GnRH antagonist protocol.
Briefly, patients who underwent the long GnRH agonist
protocol started leuprolide acetate (Lupron; Farma Laigle for
Takeda, France) in the mid-luteal phase of the preceding cycle,
and patients who received the short GnRH agonist protocol
started leuprolide acetate from Day 2 of their menses. Trans-
vaginal ultrasound and serum laboratory endocrine level
assessment were then performed on Day 2 of their menses to
confirm pituitary suppression. Controlled ovarian stimulation
was initiated until the day of oocyte maturation trigger.
Superovulation was obtained through the use of gonadotro-
pins. Patients who received the GnRH antagonist protocol
were evaluated on Day 2 of their menses, and gonadotropins
were administered. Cetrorelix (Cetrotide; Baxter Oncology,
GmbH, Germany) was initiated daily once the leading follicle
was 14 mm and was continued until the day of trigger. All
patients received recombinant gonadotropin Follitropin
a (Gonal-F; Merck Serono, SpA, Rome, Italy) at appropriate
daily doses (75e225 IU) for ovarian stimulation.
When the leading follicles reached 18e20 mm in diameter,
final oocyte maturation was induced through a subcutaneous
injection of 250-mg recombinant human chorionic gonado-
tropin (hCG; Ovitrelle, Merck Serono, SpA), and transvaginal
oocyte retrieval was performed 34e36 hours later. Oocyte
insemination, intracytoplasmic sperm injection, and in vitro
embryo culture were performed according to standard
protocol. Fertilization was assessed the next day (Day 1) and
embryo cleavage 24 hours later. Embryo morphology was
studied on Day 3 based on the number of cells and fragmen-
tation using the standard morphological criteria. A good Day 3
embryo was defined as one with the number of blastomeres
greater than or equal to eight, fragmentation of less than 20%,
and without multinucleated blastomeres. All ET procedure
was carried out on Day 3 with good-quality embryos. The
same equipment and technique was used for all ETs. Only
easy ETs have been accepted for the study. No complication of
ET procedure was noted in this study.
The luteal phase was supported by transvaginal proges-
terone gel (Crinone 8%; Fleet Laboratories Ltd., Hertford-
shire, UK) in all patients. Serum hCG was assayed 14 days
after ET; in the case of positive hCG (serum hCG level
> 30 mIU/mL), pregnancy was confirmed by transvaginal
ultrasound to detect the presence of one or more gestational
sacs 1 week later. Clinical pregnancy was defined as ultra-
sound detection of an intrauterine gestational sac with a fetal
pole and cardiac activity between 6 weeks’ and 7 weeks’
gestational age.Endpoint and statistical analysisThe primary endpoint of the study was implantation rate.
Secondary endpoints were clinical pregnancy rate, live birth
rate, incidence of adverse effects, and complications. Data
were expressed as percentages and mean standard deviations.
Table 1
Patient characteristics
Group and parameter Group 1 (n¼ 80)
(control group)
Group 2 (n¼ 40) (single bolus
dose of Tractocile)
Group 3 (n¼ 30) (infusion
dose of Tractocile)
p
Age (mean) 34.8 3.76 34.63 4.21 35.3 3.59 0.76
Number of previous failed cycles 3.08 0.93 2.6 0.54 3.2 0.79 0.11
Length of infertility (yr) 4.45 2.36 4.98 3.06 4.67 2.81 0.59
Body mass index 22.03 3.24 21.63 3.06 21.14 2.23 0.39
Etiology of infertility
Tubal factor 31.25 (25/80) 32.5 (13/40) 36.67 (11/30) 0.68
Male factor 36.25 (29/80) 32.5 (13/40) 26.67 (8/30) 0.61
Anovulation 13.75 (11/80) 17.5 (7/40) 10 (3/30) 0.47
Unexplained infertility 18.75 (15/80) 17.5 (7/40) 26.67 (8/30) 0.59
Values are expressed as mean standard deviation, and percentages, and also the number of positive finding/the total number in the group.
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continuous variables. All p values were two sided, and values
less than 0.05 were considered statistically significant.Results
Group characteristics are summarized in Table 1. There
were no significant differences among the three groups in
terms of age, number of previous cycles, length of infertility,
etiology of infertility, or body mass index. Table 2 shows the
reproductive outcomes of all groups. There were no significant
differences among the three groups in terms of the mean
number of good-quality embryos transferred.
Patients in Group 2 experienced a significantly higher
implantation rate (30.21%) compared with those of Groups 1
and 3 (11.8% and 15.9%, respectively; p¼ 0.0006). The clinical
pregnancy rate was significantly increased to 37.5% in Group 2
versus 12.5% in Group 1 and 20% in Group 3 (p¼ 0.0057). In
addition, a significant increase in the live birth rate was
observed in Group 2 (35%) compared with those in Groups 1
and 3 (10% and 16.67%, respectively; p¼ 0.0031). Although
the multiple pregnancy rate seemed higher and the miscarriage
rate seemed lower in Group 2, there were no significant
differences in the multiple pregnancy rate or the miscarriage
rate between the groups (Table 2).
No relevant adverse effects were observed in Groups 2 and 3.
One patient experienced mild nausea and another experiencedTable 2
Clinical outcome of the study
Group and parameter Group 1 (n¼ 80)
(control group)
Group
dose o
Number of embryos transferred (mean) 2.23 1.10 2.35
Implantation ratea 11.8 (21/178) 30.21 (
Clinical pregnancy rate 12.5 (10/80) 37.5 (1
Miscarriage rate 20 (2/10) 6.67 (1
Live birth rate 10 (8/80) 35 (14
Multiple pregnancy rate 10(1/10) 40 (6/1
Values are expressed as mean standard deviation, percentages, and also the num
*p Values less than 0.05 were considered statistically significant.
a Number of gestational sacs detected by ultrasound/number of transferred embrmild abdominal discomfort, but these symptoms were probably
not associated with the use of atosiban.
Discussion
The causes of RIF in assisted reproduction are complex and
numerous, which include embryonic defects, abnormalities
of the uterine cavity, reduced endometrial receptivity, or
multifactorial causes (e.g. immune system, hydrosalpinx, and
genetic). Good quality of embryos and optimal intrauterine
environment are the basic determinants of the whole IVFeET
procedure. When RIF is associated with good-quality embryos,
a uterine or endometrial factor is more likely to be present
[12]. Implantation and pregnancy rates are inversely correlated
with the frequency of uterine contractions. Increased uterine
contractile activity may expel embryos from the uterus [13]. As
psychological stressors are associated with preterm labor [14],
elevated uterine contractile activity (a component of uterine
receptivity) may also be related to the increase of stress or
anxiety during ET. In RIF, psychological factors should also be
evaluated. One study reports that more than 40% of infertile
women whowere seen for a new course of assisted reproductive
technology treatment had a psychiatric disorder (anxiety and/or
depression) [15]. The negative impact of the psychological
stress may contribute to implantation failure, which in turn
reduces IVF success [16]. Psychological stress may be associ-
ated with uterine contractility and poor IVF outcomes. The
intervention of psychological support and drug prescription2 (n¼ 40) (single bolus
f Tractocile)
Group 3 (n¼ 30) (infusion
dose of Tractocile)
p
0.99 2.37 1.14 0.85
29/96) 15.9 (11/69) 0.0006*
5/40) 20 (6/30) 0.0057*
/15) 16.6 (1/6) 0.62
/40) 16.67 (5/30) 0.0031*
5) 16.67 (1/6) 0.22
ber of positive finding/the total number in the group.
yos.
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improve the IVF outcome in anxious or depressed patients
with RIF.
One study reports that atosiban was used in pregnancies
with extremely preterm premature rupture of membranes (at
18 weeks) and assisted in prolonging a pregnancy successfully
[17]. Similarly, atosiban may increase the success rates of
infertility treatment through a possible reduction in the uterine
contractile activity, which may help increase uterine recep-
tivity during ET, especially in women with RIF. Pierzynski
et al [9] first reported that atosiban reduced intense sponta-
neous uterine contractility as visualized by transvaginal
sonography, leading to improved uterine receptivity and
resulting in successful embryo implantation during ET after
endometrial synchronization with the donated oocyte recip-
ient. Subsequently, we presented a woman who was first
treated with atosiban for RIF and successfully conceived [10].
The delivery of her second and third triplets during preterm
labor was then delayed through the use of an atosiban infusion.
Thus, atosiban has been used to inhibit uterine contractility in
both nonpregnant and pregnant women. Recently, Moraloglu
et al [11] demonstrate that treatment with atosiban before ET
affects the endometrial environment, including a decrease in
uterine contractile activity, an increase in endometrial perfu-
sion, and the inhibition of endometrial prostaglandin produc-
tion, which improves pregnancy outcomes of IVFeET.
A significant decrease in uterine contractility activity visu-
alized by transvaginal sonography has been noted after 1 hour
of intravenous atosiban infusion [9]. Although we did not use
ultrasonography to study uterine contractility after intravenous
infusion of atosiban in this study, patients in Group 2 had
a significantly higher implantation rate (30.21%) compared
with those of the control group (Group 1: 11.8%). Similarly,
patients in Group 3 had a slightly higher implantation rate
(15.9%) than those in the control group. A plausible explana-
tion for the benefits of atosiban during ET may be a decrease in
uterine contractile activity, which results in a significantly
higher embryo implantation rate. In this study, we noted that
the multiple pregnancy rate of Group 2 was coincidentally
higher than those of Groups 1 and 3. Because the patients in
our study had experienced two or more previous IVF failures,
elective single ET seemed unsuitable for them. However, the
subject of reducing the likelihood of multiple pregnancies in
women with RIF requires more investigation.
Examination between the dosage of atosiban and our
endpoints revealed that the dosage of atosiban was inversely
correlated with implantation rate, clinical pregnancy rate, and
live birth rate. Moraloglu et al [11] have demonstrated that the
total administered dose of atosiban treatment in IVFeET is
37.5 mg, with 46.7% clinical pregnancy rate and 20.4%
implantation rate. This atosiban dosage is between the
administered dosages of Groups 2 and 3 in our study, but it
still shows high pregnancy outcomes. The inverse correlation
between atosiban dosage and implantation rate seems contra-
dictory. The reason for this contradiction is unknown.
Genetic expression of oxytocin and its receptor is detected
in human cumulus cells surrounding the oocytes [18].Oxytocin may enhance blastocyte formation and play a phys-
iological role in embryogenesis of fertilized mouse oocytes.
Messenger RNA expression of the oxytocin receptor has been
demonstrated in mouse oocytes and embryos up to the blas-
tocyst stage [19]. Its expression increases immediately after
fertilization, which is compatible with a possible role of
oxytocin in this process, and then, oxytocin receptor
messenger RNA gradually decreases after the four-cell stage
of pre-embryonic development [19]. Besides, oxytocin
advanced the leutinizing hormone surge, and oxytocin is
a component of an autocrine/paracrine intraovarian regulatory
system responsible for the episodic release of progesterone
from the bovine corpus luteum during the early luteal phase.
Conversely, atosiban significantly reduces the number of
progesterone peaks, and it affects the endocrinology of the
ovulation cycle in nonpregnant women [20,21]. The pharma-
cokinetics of atosiban in nonpregnant patients is similar to that
in pregnant women [22]. Preimplantation rabbit embryo
development is not affected by atosiban in concentrations 50-
fold higher than the mean plasma concentration reached
during regular therapy [23]. In this study, no significant
maternal complications or fetal anomalies were noted in the
atosiban-treated group compared with those in the control
group. However, the suitable dosage of atosiban used in
humans during ET still needs to be clarified.
Results of this study clearly showed a significant
improvement in implantation rate, pregnancy rate, and live
birth rate in the atosiban-treated group compared with those
in the control group. To our knowledge, this is the first case-
series study evaluating the efficacy of using different dosages
of atosiban in patients with RIF undergoing IVFeET.
Although the small sample sizes of our groups limited the
statistical power of our observation, this study demonstrated
that patients with RIF may benefit from atosiban treatment.
In summary, we suggest that the use of atosiban may be safe
and effective for IVFeET of women with RIF. The use of
atosiban likely inhibits uterine contractility, which may be
a good method to help minimize the psychological burden
after consultation in women undergoing IVFeET, especially
women with RIF. Atosiban may improve pregnancy
outcomes of IVFeET in women with RIF. However, further
well-designed, prospective randomized placebo-controlled
trials with large numbers of patients are needed to compare
variant dosages of atosiban infusion during ET in women
with RIF.
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